Legal17 Apr 2025, 12:14 am
Zydus Lifesciences Loses Patent Litigation Against Astellas Pharma Inc., US
AI Summary
Zydus Lifesciences Ltd has lost a patent litigation matter in the United States District Court for the District of Delaware against Astellas Pharma Inc., USA. The litigation pertains to the validity of a patent held by Astellas Pharma Inc. for a sustained release formulation of ‘mirabegron’ marketed in the US by the innovator under the brand name Myrbetriq®. The Company believes that today's material price movement in the equity shares of the Company is due to the announcement of this order. The Company is currently evaluating the potential impact of the said order on its operations and the legal remedies available.
Key Highlights
- Zydus Lifesciences Ltd has lost a patent litigation matter in the United States District Court for the District of Delaware.
- The litigation pertains to the validity of a patent held by Astellas Pharma Inc. for a sustained release formulation of ‘mirabegron’ marketed in the US by the innovator under the brand name Myrbetriq®.
- The Company is currently evaluating the potential impact of the said order on its operations.
- The Company believes that today's material price movement in the equity shares of the Company is due to the announcement of this order.
- The Company was about to provide necessary disclosure to the stock exchanges in terms of the prescribed time limit under regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.